trial

SUSTAIN-6

Definition

Cardiovascular outcomes for semaglutide in type 2 diabetes at high CV risk (Marso et al., NEJM 2016): a 26% relative reduction in three-point MACE. It confirmed what LEADER had signaled for the class.

SUSTAIN-6 trial deep-dive

GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature. Not one of them is an AI-generated summary.

Other terms under trial

Where the evidence lives